Core Insights - A study by the American Cancer Society indicates that only about 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant opportunity to improve early detection and potentially prevent approximately 62,110 lung cancer deaths over five years [1] Company Developments - Tempus AI, Inc. has partnered with Median Technologies to integrate the eyonis LCS solution into the Tempus Pixel platform, enhancing lung cancer screening capabilities with AI-based software [2] - The company received FDA 510(k) clearance for its Tempus ECG-Low EF software, which identifies patients with low left ventricular ejection fraction [3] - Tempus strengthened its imaging capabilities through the acquisition of Arterys in 2022, integrating AI-driven imaging tools into its ecosystem [4] Peer Updates - GE HealthCare launched the Voluson Performance series and acquired icometrix to enhance its AI-powered brain imaging analysis capabilities [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' shares have declined by 14.3% over the past year, while the industry has seen a 33.6% decline, contrasting with a 17.7% increase in the S&P 500 [7] - The company currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 6.45X, above the industry average of 5.66X [11] Earnings Estimates - Tempus AI's loss per share estimate for 2025 has remained unchanged over the past 30 days, with current estimates at -$0.59 for the current year and -$0.21 for the next year [12][13]

Buffalo, NY, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners, along with associated long-term services agreements, to three distinguished nuclear cardiology practices led by nationally recognized physicians specializing in advanced cardiovascular diagnostics and interventional care. These new customer engagements underscore the adoption of Pos ...

Core Insights - Nanox Imaging Ltd will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the European Congress of Radiology (ECR) from March 4-8, 2026, in Vienna, Austria [1][5] Product Overview - The Nanox.ARC is a CE-marked and FDA-cleared multi-source digital tomosynthesis system that enables 3D imaging at a lower cost and significantly reduced radiation dose compared to traditional CT [2][4] - The system's smaller footprint and simplified installation make it suitable for various European healthcare settings, from major medical centers to community clinics [2][4] Demonstrations and Presentations - Live demonstrations of the Nanox.ARC will occur every 30 minutes at booth 425 during the ECR [3][6] - New clinical data on the role of digital tomosynthesis in lung cancer screening will be presented, along with the TAP2D cloud-enabled image enhancement [3][4] - Oral presentations will cover the potential of digital tomosynthesis in lung cancer screening and the role of AI in CT imaging [5][6] AI Solutions - Nanox will showcase its FDA-cleared AI solutions that analyze routine CT scans for chronic disease indicators, including the AI Cardiac solution (HealthCCSng), AI Bone solution (HealthOST), and AI Liver solution (HealthFLD) [4][9] - Two new AI solutions under development for aortic valve calcification and body composition measurement will also be presented [4] Clinical Studies - Poster presentations will feature new data from the ADOPT study conducted in the UK, highlighting the impact of AI-enabled vertebral fracture identification on clinical workflows and treatment recommendations [4][8] Company Vision - Nanox aims to drive the transition to preventive healthcare by providing an integrated medical imaging and healthcare services platform, combining affordable imaging hardware, advanced AI solutions, and cloud-based software [9][10] - The company's vision includes expanding the reach of medical imaging beyond traditional hospital settings to enhance efficiency and support early disease detection [10][12] Ecosystem Components - The Nanox ecosystem includes the Nanox.ARC imaging system, Nanox.AI for AI-based algorithms, Nanox.CLOUD for data management, and Nanox Health IT for healthcare IT solutions [11]

Core Insights - Royal Philips has launched the InkSpace Imaging Snuggle™ pediatric body array coil for its 3.0T MRI systems, aimed at enhancing comfort for pediatric patients and improving imaging efficiency for clinicians [1][4]. Group 1: Product Features - The Snuggle coil is designed specifically for pediatric patients, featuring a light, blanket-like design that wraps gently around the child, making MRI exams less intimidating [2]. - Its high-density array and flexible structure enable sharp, high-resolution images, allowing for more efficient exams across various pediatric anatomies, which can reduce the need for additional imaging or follow-up procedures [3]. Group 2: Collaboration and Development - The collaboration between Philips and InkSpace Imaging focuses on pediatric design, combining Philips' MRI leadership with InkSpace Imaging's expertise to create a child-friendly alternative to traditional rigid devices [4]. - The Snuggle coil has been cleared through the U.S. FDA 510(k) process, indicating its safety and effectiveness for use in pediatric imaging [4]. Group 3: Market Availability and Future Plans - The Snuggle pediatric coil is currently available in the United States, with plans for rollout to additional regions in the future [5]. - Philips and InkSpace Imaging are exploring further opportunities to expand coil technology that emphasizes comfort and efficiency, aiming to support healthcare professionals and families [5]. Group 4: Company Overview - Royal Philips is a leading health technology company with a focus on improving health and well-being through innovation, generating sales of EUR 18 billion in 2025 and employing approximately 64,800 people globally [7].

Core Insights - Varex Imaging reported a strong start to fiscal year 2026, with first-quarter revenue of $210 million, a 5% increase year-over-year, driven by a 17% increase in the Industrial segment and stable performance in the Medical segment [5][16] - The company highlighted a favorable product sales mix contributing to a non-GAAP gross margin of 34%, and non-GAAP EPS of $0.19, up from $0.10 in the previous year [6][20] - Engagement with customers at the RSNA conference indicated a positive outlook for future demand, particularly in the Medical segment, with a focus on innovation and integration of technologies [10][12] Financial Performance - First-quarter revenue was $210 million, with Medical segment revenue at $145 million (69% of total) and Industrial segment revenue at $65 million (31% of total) [16] - Non-GAAP EBITDA for the quarter was $29 million, reflecting a 12% increase year-over-year [6] - Operating income was reported at $19 million, with an operating margin of 9%, up from 7% in the same quarter last year [20] Segment Performance - The Industrial segment showed strong growth, particularly in cargo security systems, which benefited from global demand [8][14] - The Medical segment remained stable, with solid demand for X-ray sources and digital detectors, although some modalities like dental and oncology were below sales trends [7][10] - The company is focusing on a modality-based approach to enhance customer engagement and drive long-term recurring revenue [11][12] Customer Engagement and Market Outlook - Increased customer engagement at RSNA, with over 150 meetings focused on design win opportunities and system upgrades [9][10] - The company is optimistic about future demand, particularly in the Medical segment, as customers shift from maintenance to new product development [13][29] - The India manufacturing strategy is seen as critical for future growth, with local production resonating well with customers [12][34] Inventory and Cash Flow - Inventory increased by $29 million to $328 million, driven by anticipated demand in the Industrial segment and qualification cycles for new products [21][62] - Net cash outflow from operations was $16 million, primarily due to inventory increases, with cash and marketable securities totaling $126 million [22][62] Guidance and Future Expectations - Guidance for the second quarter anticipates revenues between $210 million and $225 million, with non-GAAP EPS expected between $0.15 and $0.25 [23] - The company expects to continue seeing strong order activity in both Medical and Industrial segments, with a focus on securing new design wins [24][31]

Core Insights - Varex Imaging reported a strong start to fiscal 2026, with first-quarter results at the high end of guidance, driven by growth in industrial markets and stable medical performance [4][3] Financial Performance - On a GAAP basis, gross margin was 33%, operating income was $15 million, net income was $2 million, and GAAP EPS was $0.05 per diluted share [1] - Non-GAAP gross margin was 34%, with non-GAAP EBITDA of $29 million, up 12% year over year, and non-GAAP EPS of $0.19, an increase from $0.10 in the previous year [2] - Total revenue for the first quarter was $210 million, reflecting a 5% year-over-year increase, with industrial segment revenue rising 17% [3][6] Revenue Breakdown - Medical revenue accounted for $145 million (69% of total revenue), while industrial revenue was $65 million (31% of total revenue) [1] - Regionally, the Americas grew by 17%, EMEA rose by 7%, and APAC declined by 7% year over year [1] Industrial Segment Insights - The industrial segment's growth was attributed to demand in cargo security systems and non-destructive testing (NDT) [11][12] - Management noted that orders in the industrial segment are "tender-driven" and can be lumpy, with potential for double-digit growth contingent on wins and shipment timing [12] Medical Segment Insights - The medical segment showed stable performance, with strong demand for X-ray sources, particularly in high-end CT, and increasing customer engagement on next-generation system designs [7][8] - Mammography exceeded sales trends, while CT, fluoroscopy, and radiography were in line with sales trends [10] Balance Sheet and Cash Flow - Inventory increased by $29 million to $328 million, leading to a $16 million operating cash outflow [5][15] - Varex ended the quarter with $126 million in cash and gross debt of $370 million, with a net leverage of approximately 1.9x [16] Future Outlook - For the second quarter, Varex guided revenue between $210 million and $225 million, with non-GAAP EPS expected to be between $0.15 and $0.25 [18] - Management expressed confidence in customer engagement across both segments, highlighting innovation in medical imaging and expanding industrial applications [17]

Core Insights - VAREX IMAGING reported revenue of $209.6 million for the quarter ended December 2025, marking a year-over-year increase of 4.9% and a surprise of +0.22% over the Zacks Consensus Estimate of $209.15 million [1] - The company achieved an EPS of $0.19, which is a significant increase from $0.07 a year ago, resulting in an EPS surprise of +35.71% compared to the consensus estimate of $0.14 [1] Revenue Performance - Industrial revenues reached $64.8 million, exceeding the estimated $61.61 million, reflecting a year-over-year increase of +17.4% [4] - Medical revenues totaled $144.8 million, slightly below the estimated $147.5 million, with a minimal year-over-year change of +0.1% [4] Profit Metrics - Gross profit from Industrial operations was reported at $23.8 million, surpassing the average estimate of $21.27 million [4] - Gross profit from Medical operations was $46 million, which fell short of the average estimate of $48.32 million [4] Stock Performance - VAREX IMAGING shares have returned +5.5% over the past month, while the Zacks S&P 500 composite remained unchanged [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Guerbet reported a 6.5% decline in sales for the full year 2025, totaling €786.4 million, with a more moderate decline of 3.8% at constant exchange rates (CER) [3][10]. Financial Performance - The decline in sales was primarily attributed to a 5.4% drop in the first half of the year, followed by a 2.6% increase in Q3, and a 5.6% decline in Q4, influenced by issues at the Raleigh industrial site in the U.S. [4][10]. - Revenue breakdown for Q4 2025 showed a total of €200.0 million, down 9.4% compared to Q4 2024, with a decline of 5.6% at CER [5][11]. Geographical Breakdown - In EMEA, full-year sales were €343.7 million, down 2.5% at CER, with a notable growth of 7.6% excluding France [7]. - The Americas reported revenue of €233.0 million, a decrease of 3.8% at CER, with a significant contraction of 8.6% in Q4 due to production delays at the Raleigh site [8]. - In Asia, sales totaled €207.9 million, down 4.8% at CER, impacted by the loss of a customer in Vietnam [9]. Segment Performance - Diagnostic Imaging revenue for the year was €678.2 million, a decrease of 5.3% at CER, with a 9.1% decline in Q4 [11]. - Interventional Imaging saw revenue increase to €106.3 million, up 9.7% at CER, driven by strong demand for Lipiodol in vascular embolization [12]. Future Outlook - The company confirmed its forecast for a restated EBITDA margin between 10.5% and 12% for 2025 and revised its Free cash flow target to be positive [13]. - The ongoing situation at the Raleigh site is expected to continue affecting revenue, profitability, and cash generation in 2026 [15][16].

Core Viewpoint - The FDA has granted 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for Nanox's digital tomosynthesis systems, marking a significant step in the company's regulatory strategy to establish its systems as primary diagnostic solutions [1][4]. Group 1: Product Development and Features - The TAP2D capability provides radiologists with an additional 2D view generated from digital tomosynthesis scans, enhancing evaluation while maintaining workflow efficiency [2]. - Nanox.ARC and Nanox.ARC X systems utilize advanced 3D imaging technology, offering enhanced diagnostic capabilities at a lower cost and radiation dose compared to traditional systems [3]. - Software upgrades and new capabilities like TAP2D can be added remotely to the Nanox.ARC systems following regulatory clearances [3]. Group 2: Company Vision and Strategy - The company aims to remove the adjunctive use of its systems in the U.S., allowing Nanox.ARC to function as a standalone primary imaging solution, similar to its status in Europe under CE Mark certification [4]. - Nanox is focused on delivering innovations that improve patient care and expand access to high-quality imaging globally [4]. - The company's vision includes expanding medical imaging access beyond traditional hospital settings by providing a seamless solution from scan to interpretation [6]. Group 3: Ecosystem and Services - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI for AI-driven analytics, Nanox.CLOUD for data management, and Nanox Health IT for healthcare IT solutions [7]. - By integrating imaging technology, AI, cloud infrastructure, and clinical expertise, Nanox seeks to lower barriers to adoption and advance preventive care worldwide [8].

Core Insights - Butterfly Network, Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, at 8:00 am ET [1] - The conference call will be hosted by Joseph DeVivo, President and CEO, and John Doherty, CFO, to discuss financial performance and operational progress [1] Company Overview - Butterfly Network is a healthcare company focused on transforming medical imaging through its proprietary Ultrasound-on-Chip™ technology and ultrasound software solutions [3] - The company launched the first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018, followed by iQ+ in 2020 and iQ3 in 2024, each with enhanced processing power [3] - The iQ3 received the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its recognition in the healthcare sector [3] Product and Market Strategy - Butterfly combines advanced hardware, intelligent software, AI, services, and education to promote the adoption of affordable and accessible imaging solutions [4] - Clinical publications indicate that Butterfly's handheld ultrasound probes, when paired with Compass™ enterprise workflow software, can improve care workflows, reduce costs, and enhance provider economics [4] - The company's cloud-based solution enables healthcare delivery anywhere, addressing significant global healthcare challenges and aiming to democratize healthcare [4] - Butterfly devices are available to trained healthcare practitioners across various regions, including parts of Africa, Asia, Australia, Europe, the Middle East, North America, and South America [4]